DX&Vx Files Patent Application for mRNA Cancer Vaccine Candidate

DXVX announced on the 29th that it will file a patent application for a candidate substance of its mRNA cancer vaccine currently under development.

DXVX plans to accelerate research and development in line with the government's large-scale 'mRNA Vaccine Localization Support Project' exempted from preliminary feasibility studies, and intends to file a substance patent for the mRNA cancer vaccine within this year.

DXVX will expand the indications of its self-developed circular mRNA cancer vaccine candidate substance to hard-to-treat cancers such as triple-negative breast cancer and improve the production process to speed up vaccine development. Triple-negative breast cancer is a type of breast cancer that tests negative for all three breast cancer markers, making conventional anticancer drugs less effective. It accounts for about 16% of all breast cancers and represents a significant unmet medical need.

DXVX expressed confidence in the government's independent mRNA vaccine project due to the efficacy and high commercialization potential of the cancer vaccine candidate substance it is developing. Preclinical efficacy of the cancer vaccine candidate substance has been confirmed in melanoma, and the company is jointly developing essential delivery technology, LNP (Lipid Nanoparticle), for mRNA vaccines with Pohang University of Science and Technology. Additionally, there is potential use of proprietary LNP technology from Luca AI Cell, founded by recently recruited global scholar Professor Namjun Cho.

Furthermore, DXVX analyzed genetic differences between cancer cells and normal cells in cancer patients by applying AI-based mRNA vaccine structural design technology. The company is already working with Hanyang University on establishing SOPs for developing personalized neoantigen-based mRNA cancer vaccines targeting neoantigens, which are genetic mutations present only in cancer cells of specific patients.

Park Sang-jin, Head of R&D Center at DXVX, stated, “DXVX plans to quickly verify anticancer effects targeting hard-to-treat cancers using independently designed mRNA cancer vaccine candidates by leveraging circular mRNA technology and innovative lipid nanoparticle (LNP) delivery system production process technology. We are preparing to file patents and apply for the government’s mRNA vaccine localization support project.”

This content was produced with the assistance of AI translation services.